SpringerLink
Log in

Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557.

    Article  CAS  Google Scholar 

  2. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.

    Article  CAS  Google Scholar 

  3. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111: 86–93.

    Article  CAS  Google Scholar 

  4. List A, Wride K, Dewald G, Bennett JM, Giagounidis A, Kurtin S et al. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion. Leuk Res 2007; 31 (suppl 1): s38.

    Article  Google Scholar 

  5. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974–12979.

    Article  CAS  Google Scholar 

  6. List A, Lancet JE, Melchert M, Saba H, Lush R, Yu Y et al. Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures (PK-002). Blood (ASH Annual Meeting Abstracts 2007; 110: Abstract 4626.

  7. Moutouh-De Parseval LA, Verhelle D, Glezer E, Jensen-Pergakes K, Ferguson GD, Corral LG et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008; 118: 248–258.

    Article  CAS  Google Scholar 

  8. List AF, Estes M, Williams A, Sekharam M, Ozawa U, Gao G et al. Lenalidomide (CC-5013; Revlimid) promotes erythropoiesis in myelodysplastic syndromes (MDS) by CD45 protein tyrosine phosphatase (PTP) inhibition [abstract]. Blood (ASH Annual Meeting Abstracts 2006; 108: Abstract 1360.

Download references

Author information

Authors and Affiliations

  1. Department of hematology, Hôpital COCHIN, University of Paris V, Paris, France

    S Park, D Vassilieff & F Dreyfus

  2. Laboratory of hematology, Hôpital COCHIN, University of Paris V, Paris, France

    V Bardet

  3. Laboratory of hematology, Hôpital Hôtel Dieu, University of Paris V, Paris, France

    F Viguié

Authors
  1. S Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Vassilieff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V Bardet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Viguié
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Dreyfus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Park.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, S., Vassilieff, D., Bardet, V. et al. Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide. Leukemia 24, 1960–1962 (2010). https://doi.org/10.1038/leu.2010.183

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.183

  • Springer Nature Limited

This article is cited by

Search

Navigation